viewIQ-AI Limited

IQ-AI posts sharply reduced losses

The first half saw increased momentum in the Gadolinium free project and increased investment in its artificial intelligence projects

IQ-AI Limited -
The company wants to eliminate the need to use gadolinium-based contrast agents in MRI scans

Investment company IQ-AI Limited (LON:IQAI) said it has entered an exciting phase in its development, as it announced its half-year results.

The company's Gadolinium free project, known as "Simulated T1+C", increased momentum during the first half of 2019.

WATCH: IQ-AI Limited in an 'exciting phase of its development'

IQ-AI's subsidiary, Imaging Biometrics, strengthened its development team and committed significant resources to accelerate the development of a product that would remove the need to use potentially harmful gadolinium-based contrast agents in magnetic resonance imaging scans.

IQ-AI said that the growing worldwide market for these agents is around US$1.8bn.

The company's goal is to complete product development within two years and be in a position to submit the product to the relevant regulatory authorities for market clearance at that time.

The other development areas the company is focusing on are artificial intelligence and machine learning, and the company beefed up developer time on these areas in the first half of 2019 and increased capital expenditure on its projects.

All of the company's products are based upon digitising information from medical imaging equipment on a voxel-wise basis – a voxel being the three-dimensional (3D) equivalent of a pixel (i.e. a point on a 3D grid).

In the technology IQ-AI is developing, each individual voxel is examined and compared to surrounding voxels, which is often the first step in identifying diseased or compromised tissue.

In a Machine Learning model, when patients are scanned, their anonymised data is sent over a secure internet feed to a server that is running Imaging Biometrics software; the hospital or clinic receives back useful information on the patient's condition while IB's database is enhanced through the addition of more information.

IQ-AI expects to develop multiple technologies as a result of this initiative and incorporate those technologies into existing and new products.

Revenue for the first six months of the year rose to £142,375 from a restated £47,021 in the same period of 2018.

Loss before income tax narrowed to £141,721 from £401,708.

Net asset value improved to £1.36mln from £255,471 the year before.

Quick facts: IQ-AI Limited

Price: 2.726 GBX

Market: LSE
Market Cap: £3.98 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...



Full interview: Pure Gold adds 12.3 million dollars to treasury bringing...

Pure Gold (CVE: PGM) CEO Darin Labrenz updated Steve Darling from Proactive Vancouver that the company has exercised 14,465 million share warrants raising 12.3 million dollars. With that capital added, the treasury now has over 100 million dollars. In fact, the company now sits with 150 million...

13 hours, 42 minutes ago

2 min read